Publikationen 2005
1: Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI,
Huland H, Jones PA, Liang G.
Prognostic relevance of methylation markers in patients with non-muscle invasive
bladder carcinoma.
Eur J Cancer. 2005 Oct 18
2: Graefen M, Salomon G, Currlin E, Eichelberg C, Schlomm T, Huland H.
Selection criteria for the expected management of localised prostate cancer
Urologe A. 2005 Oct 5; German.
3: Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, Ergun S.
Stage-dependent increase of orosomucoid and zinc-alpha(2)-glycoprotein in urinary
bladder cancer.
Proteomics. 2005 Nov;5(16):4296-304.
4: Heinzer H, Heuer R, V Nordenflycht O, Eichelberg C, Friederich P, Goetz AE,
Huland H.
Fast-track surgery in radical retropubic prostatectomy First experiences with a
comprehensive program to enhance postoperative convalescence
Urologe A. 2005 Sep 23; German.
5: Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, Kattan MW,
Eastham JA, Scardino PT, Huland H, Lilja H.
Risk assessment for biochemical recurrence prior to radical prostatectomy:
Significant enhancement contributed by human glandular kallikrein 2 (hK2) and
free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Int J Cancer. 2005 Sep 8
6: Leuenroth S, Riethdorf S, Erbersdobler A, Riethdorf L, Loning T, Huland H,
Friedrich MG.
Detection of human telomerase RNA in the tumour-surrounding mucosa of bladder
carcinomas as a marker for premalignant transformation.
BJU Int. 2005 Sep;96(4):553-7.
7: Schlomm T, Luebke AM, Sultmann H, Hellwinkel OJ, Sauer U, Poustka A, David KA,
Chun FK, Haese A, Graefen M, Erbersdobler A, Huland H.
Extraction and processing of high quality RNA from impalpable and macroscopically
invisible prostate cancer for microarray gene expression analysis.
Int J Oncol. 2005 Sep;27(3):713-20.
8: Bostwick DG, Adolfsson J, Burke HB, Damber JE, Huland H, Pavone-Macaluso M, Waters DJ.
Epidemiology and statistical methods in prediction of patient outcome.
Scand J Urol Nephrol Suppl. 2005 May;(216):94-110.
9: Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H.
Reasonable delay of surgical treatment in men with localized prostate cancer-
impact on prognosis?
Eur Urol. 2005 Jun;47(6):756-60. Epub 2005 Mar 2.
10: Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT,
Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M.
Development and validation of a nomogram predicting the outcome of prostate biopsy
based on patient age, digital rectal examination and serum prostate specific antigen.
J Urol. 2005 Jun;173(6):1930-4.
11: Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C,
Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R,
Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S,
Marberger MJ, Karakiewicz PI.
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and
progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
J Urol. 2005 May;173(5):1518-25.
12: Meraney AM, Haese A, Palisaar J, Graefen M, Steuber T, Huland H, Klein EA.
Surgical management of prostate cancer: advances based on a rational approach to the data.
Eur J Cancer. 2005 Apr;41(6):888-907. Review.
13: Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H,
Sokoll LJ, Partin AW.
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c
prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined
with clinical stage and Gleason grade.
J Urol. 2005 Mar;173(3):752-6.
14: Steuber T, Karakiewicz PI, Augustin H, Erbersdobler A, Lange I, Haese A, Chun KH, Walz J,
Graefen M, Huland H.
Transition zone cancers undermine the predictive accuracy of Partin table stage predictions.
J Urol. 2005 Mar;173(3):737-41.
15: Palisaar RJ, Noldus J, Graefen M, Erbersdobler A, Haese A, Huland H.
Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status
and biochemical failure.
Eur Urol. 2005 Feb;47(2):176-84.
16: Augustin H, Erbersdobler A, Hammerer PG, Graefen M, Huland H.
Prostate cancers in the transition zone: Part 2; clinical aspects.
BJU Int. 2004 Dec;94(9):1226-9. Review. No abstract available.
17: Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H,
Friedrich M, Ergun S.
Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and
invasion of human urinary bladder cancer.
Cancer Res. 2004 Dec 15;64(24):8932-8.
18: Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Toma MI,
Huland H, Yoo C, Tsai YC, Nichols PW, Bochner BH, Jones PA, Liang G.
Detection of methylated apoptosis-associated genes in urine sediments of bladder
cancer patients.
Clin Cancer Res. 2004 Nov 15;10(22):7457-65.
19: Hautmann S, Friedrich MG, Fernandez S, Steuber T, Hammerer P, Braun PM,
Junemann KP, Huland H.
Extracorpereal shockwave lithotripsy compared with ureteroscopy for the removal of small
distal ureteral stones.
Urol Int. 2004;73(3):238-43.
20: Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH,
Graefen M, Kattan MW, Huland H, Lilja H.
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2
with volume of benign and malignant prostatic tissue.
Prostate. 2005 Apr 1;63(1):13-8.
21: Hautmann S, Toma M, Lorenzo Gomez MF, Friedrich MG, Jaekel T, Michl U, Schroeder GL,
Huland H, Juenemann KP, Lokeshwar VB.
Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Eur Urol. 2004 Oct;46(4):466-71.
22: Toma MI, Friedrich MG, Hautmann SH, Jakel KT, Erbersdobler A, Hellstern A, Huland H.
Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection
and surveillance of bladder cancer.
World J Urol. 2004 Jun;22(2):145-9. Epub 2004 Feb 27.
23: Friedrich MG, Toma MI, Petri S, Huland H.
Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not
predict recurrence.
BJU Int. 2003 Sep;2(4):389-92.
